title: Nano-hydroxyapatite/β-tricalcium phosphate ceramics scaffolds loaded with cationic liposomal ceftazidime: preparation, release characteristics in vitro and inhibition to Staphylococcus aureus biofilms.
abstract: In the current study, nano-hydroxyapatite/β-tricalcium phosphate (HA/β-TCP) ceramics scaffolds loaded with cationic liposomal ceftazidime (CLCs) prepared by modified reverse phase evaporation method, the investigations of their release characteristics were performed by the dissolution tests, in vitro anti-biofilm activity of the scaffolds was studied by the determination of bacterial susceptibility with ELISA. The mean particle size, zeta potential, pH and entrapment efficiency of the CLCs studied were 161.5 ± 5.37 nm, 60.60 ± 5.24 mV, 6.90 ± 0.07 and 16.57 ± 0.13%, respectively. Electron microscopic images of the samples indicated that the liposomes were well preserved in the scaffolds and that it was the CLCs rather than free ceftazidime releasing from the scaffolds. The minimal inhibitory concentrations (MICs) to Staphylococcus aureus of free ceftazidime and its liposomal formulation were 6.00 μg/mL and the release behaviors of both CLCs and free ceftazidime from scaffolds were based on the dissolution/diffusion processes, Fick's law. These results demonstrated that CLCs could inhibit remarkably the formation of S. aureus biofilm more effectively than free ceftazidime (P < 0.05). The study demonstrated that the HA/β-TCP ceramic scaffolds was such a material that could sustain release CLCs and maintain the adequate amounts of CLCs to absorb to biofilm. It provided an ideal way to inhibit bacterial biofilms for clinical practices.
authors.affiliation: Kuming General Hospital of Chengdu Military Region, Kuming, Yunnan, China 650032.
authors.forename: Tian-Hua
authors.initials: TH
authors.lastname: Zhou
authors.forename: Min
authors.initials: M
authors.lastname: Su
authors.forename: Bei-Cheng
authors.initials: BC
authors.lastname: Shang
authors.forename: Tao
authors.initials: T
authors.lastname: Ma
authors.forename: Gui-Li
authors.initials: GL
authors.lastname: Xu
authors.forename: Hong-Liang
authors.initials: HL
authors.lastname: Li
authors.forename: Qing-Hua
authors.initials: QH
authors.lastname: Chen
authors.forename: Wei
authors.initials: W
authors.lastname: Sun
authors.forename: Yong-Qing
authors.initials: YQ
authors.lastname: Xu
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D001672:Biocompatible Materials / Q000737:chemistry*; D018441:Biofilms / Q000187:drug effects*; D018786:Bone Substitutes / Q000737:chemistry; D002412:Cations; D002442:Ceftazidime / Q000008:administration & dosage / Q000737:chemistry* / Q000494:pharmacology; D002516:Ceramics / Q000737:chemistry*; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D006882:Hydroxyapatites / Q000737:chemistry*; D008081:Liposomes; D008826:Microbial Sensitivity Tests; D008855:Microscopy, Electron, Scanning; D049329:Nanostructures / Q000737:chemistry*; D016062:Porosity; D012995:Solubility; D013211:Staphylococcus aureus / Q000187:drug effects / Q000502:physiology; D013499:Surface Properties
chemical_list: D000900:Anti-Bacterial Agents; D001672:Biocompatible Materials; D018786:Bone Substitutes; D002412:Cations; D004337:Drug Carriers; D006882:Hydroxyapatites; D008081:Liposomes; C074950:hydroxyapatite-beta tricalcium phosphate; D002442:Ceftazidime